SHEN211 / JKT Biopharma - LARVOL DELTA

Absorption, distribution, metabolism, and excretion of [14C]SHEN211, a nonpeptidic small-molecule 3CLpro inhibitor, in rats. (PubMed, J Pharmacol Exp Ther) - "Fecal excretion was the primary elimination route. The prediction of human pharmacokinetic characteristics using the physiologically based pharmacokinetic model provides an invaluable reference for optimizing the clinical dosing strategy of SHEN211 and advancing its ongoing clinical trials in China."

Journal • Preclinical • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Phase II Clinical Study of SHEN211 Tablets in the Treatment of Mild and Moderate Novel Corona Virus Infection (COVID-19) (clinicaltrials.gov) - P2 | N=30 | Not yet recruiting | Sponsor: JKT Biopharma Co., Ltd.

New P2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases